CoronaryAtlas logo
CoronaryAtlas
CD16
Pathway / Plaque inflammation

CD16

FCGR3Aprotein

CD16 identifies pro-inflammatory monocyte subsets that are enriched in acute coronary syndromes and drive vascular inflammation and platelet activation during atherothrombotic MI.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleNon-classical monocyte subset marker; pro-inflammatory in acute coronary events.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000203747

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
63
C — confounder / Type-II
91
A — assay feasibility
72
E — evidence strength
34
T1DI (composite)
9
Specificity differential (R−C)-28.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)